European Neuropsychopharmacology

1

Signs of striatal dopamine transporter density increase in association with improvement of tardive dyskinesia in a patient with schizophrenia, as demonstrated by a DAT scan

E.N. Rizos, S. Chatziioannou, A. Douzenis, N. Siafakas, E. Katsantoni, P. Nikolaidou, M. Papathanasiou, L. Lykouras

Journal:

Year:

2010

Language:

english

File:

PDF, 412 KB

english, 2010

2

Effects of escitalopram on stress-related relapses in women with multiple sclerosis: An open-label, randomized, controlled, one-year follow-up study

Charalampos I. Mitsonis, Iannis M. Zervas, Constantin M. Potagas, Panagiotis A. Mitropoulos, Nikolaos P. Dimopoulos, Constantin A. Sfagos, George N. Papadimitriou, Demetrios C. Vassilopoulos

Journal:

European Neuropsychopharmacology

Year:

2010

Language:

english

File:

PDF, 431 KB

english, 2010

3

Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder

Johannes Tauscher, William Kielbasa, Smriti Iyengar, Francois Vandenhende, Xiaomei Peng, David Mozley, Donald R. Gehlert, Gerard Marek

Journal:

European Neuropsychopharmacology

Year:

2010

Language:

english

File:

PDF, 433 KB

english, 2010

4

The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: A review

Cleo L. Crunelle, Michelle L. Miller, Jan Booij, Wim van den Brink

Journal:

European Neuropsychopharmacology

Year:

2010

Language:

english

File:

PDF, 246 KB

english, 2010

5

Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: Comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142

K.S. Sink, K.N. Segovia, J. Sink, P.A. Randall, L.E. Collins, M. Correa, E.J. Markus, V.K. Vemuri, A. Makriyannis, J.D. Salamone

Journal:

European Neuropsychopharmacology

Year:

2010

Language:

english

File:

PDF, 486 KB

english, 2010

6

A mouse model of anxiety molecularly characterized by altered protein networks in the brain proteome

Éva M. Szegő, Tamás Janáky, Zoltán Szabó, Attila Csorba, Hajnalka Kompagne, Géza Müller, György Lévay, Attila Simor, Gábor Juhász, Katalin A. Kékesi

Journal:

European Neuropsychopharmacology

Year:

2010

Language:

english

File:

PDF, 836 KB

english, 2010

7

Evaluation of the effect of selective serotonin-reuptake inhibitors on lymphocyte subsets in patients with a major depressive disorder

Maria Eugenia Hernandez, Daniel Martinez-Fong, Mayra Perez-Tapia, Iris Estrada-Garcia, Sergio Estrada-Parra, Lenin Pavón

Journal:

European Neuropsychopharmacology

Year:

2010

Language:

english

File:

PDF, 490 KB

english, 2010

8

Erratum to “Effect of basic fibroblast growth factor (FGF2) gene polymorphisms on SSRIs treatment response and side effects” [Eur. Neuropsychopharmacol. 19 (2009) 718–725]

Masaki Kato, Gaku Okugawa, Masataka Wakeno, Yoshiteru Takekita, Shinpei Nonen, Shinji Tetsuo, Keiichiro Nishida, Junichi Azuma, Toshihiko Kinoshita, Alessandro Serretti

Journal:

European Neuropsychopharmacology

Year:

2010

Language:

english

File:

PDF, 85 KB

english, 2010

9

Editorial Board

Journal:

European Neuropsychopharmacology

Year:

2010

Language:

english

File:

PDF, 413 KB

english, 2010

10

ECNP Calendar of Events

Journal:

European Neuropsychopharmacology

Year:

2010

Language:

english

File:

PDF, 637 KB

english, 2010

11

Volume 20; Issue 2

Signs of striatal dopamine transporter density increase in association with improvement of tardive dyskinesia in a patient with schizophrenia, as demonstrated by a DAT scan

Effects of escitalopram on stress-related relapses in women with multiple sclerosis: An open-label, randomized, controlled, one-year follow-up study

Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder

The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: A review

Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: Comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142

A mouse model of anxiety molecularly characterized by altered protein networks in the brain proteome

Evaluation of the effect of selective serotonin-reuptake inhibitors on lymphocyte subsets in patients with a major depressive disorder

Erratum to “Effect of basic fibroblast growth factor (FGF2) gene polymorphisms on SSRIs treatment response and side effects” [Eur. Neuropsychopharmacol. 19 (2009) 718–725]

Editorial Board

ECNP Calendar of Events

Contents